D. E. Shaw & Co., Inc. Aquestive Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$122 Billion
Q4 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 126,464 shares of AQST stock, worth $354,099. This represents 0.0% of its overall portfolio holdings.

Number of Shares

126,464

Previous 31,046 307.34%

Holding current value

$354,099

Previous $154,000 190.26%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$3.46 - $5.64 $330,146 - $538,157	95,418 Added 307.34%	126,464 $447,000
Q3 2024 Nov 14, 2024	BUY	$2.4 - $5.09 $50,059 - $106,167	20,858 Added 204.73%	31,046 $154,000
Q2 2024 Aug 14, 2024	SELL	$2.31 - $4.5 $196,407 - $382,612	-85,025 Reduced 89.3%	10,188 $26,000
Q1 2024 May 15, 2024	BUY	$2.01 - $6.09 $191,378 - $579,847	95,213 New	95,213 $405,000
Q2 2022 Aug 15, 2022	BUY	$0.64 - $2.57 $35,692 - $143,326	55,769 Added 51.24%	164,607 $106,000
Q1 2022 May 16, 2022	BUY	$2.28 - $4.26 $47,998 - $89,681	21,052 Added 23.98%	108,838 $284,000
Q4 2021 Feb 14, 2022	BUY	$3.69 - $6.37 $323,930 - $559,196	87,786 New	87,786 $341,000
Q3 2020 Nov 16, 2020	SELL	$4.12 - $9.09 $1.17 Million - $2.58 Million	-283,418 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.84 - $6.44 $127,320 - $445,622	69,196 Added 32.3%	283,418 $1.38 Million
Q1 2020 May 15, 2020	SELL	$1.54 - $6.75 $75,760 - $332,066	-49,195 Reduced 18.68%	214,222 $469,000
Q4 2019 Feb 14, 2020	BUY	$3.06 - $8.78 $806,056 - $2.31 Million	263,417 New	263,417 $1.53 Million

Others Institutions Holding AQST

# of Institutions

121

Shares Held

43.3M

Call Options Held

504K

Put Options Held

148K

View Full List

About Aquestive Therapeutics, Inc.

Ticker AQST
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,350,700
Market Cap $149M
Description
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...

More about AQST

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account